Generic substitution in the treatment of epilepsy: Patient and physician perceptions

Epilepsy and Behavior

Volumn 13, Issue 4, 2008, Pages 693-699

  Berg, Michel J ^a   Gross, Robert A ^a,b   Haskins, Lisa S ^c   Zingaro, Wendy M ^c   Tomaszewski, Kenneth J ^b,d  

^a STRONG MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Harris Interactive   (United States)

^d KJT Group   (United States)

Author keywords

All epilepsy seizure; Antiepileptic drugs; Generic; Outcome research; Quality of life; Substitution

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DEPAKOTE ER; ETIRACETAM; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ADULT; ARTICLE; DISEASE CONTROL; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; GENERAL PRACTITIONER; GENERALIZED EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; PRESCRIPTION; SEIZURE; SELF REPORT;

ANTICONVULSANTS; DRUGS, GENERIC; EPILEPSY; FEMALE; HEALTH SURVEYS; HUMANS; MALE; PERCEPTION; PHYSICIANS; THERAPEUTIC EQUIVALENCY; UNITED STATES;

EID: 54049099905     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2008.06.001     Document Type: Article

References (20)

1. Haas J.S., Phillips K.A., Gerstenberger E.P., and Seger A.C. Potential savings from substituting generic drugs for brand-name drugs: Medical Expenditure Panel Survey, 1997-2000. Ann Intern Med 142 (2005) 891-897
2. Schwartz L.L. The debate over substitution policy: its evolution and scientific basis. Am J Med 79 2B (1985) 38-44
3. Center for Drug Evaluation and Research (CDER). Immediate release solid oral dosage forms scale-up and postapproval changes: chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation. 1995. Available at:http://www.fda.gov/cder/guidance/cmc5.pdf.
4. Guberman A., and Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci 27 (2000) 37-43
5. Crawford P., Feely M., Guberman A., and Kramer G. Are there potential problems with generic substitution of antiepileptic drugs?. A review of issues. Seizure 15 (2006) 165-176
6. National Association of Boards of Pharmacy. Survey of pharmacy law-2006. Mount Prospect, IL; 2005.
7. Hamilton D. A brief history of the Center for Drug Evaluation and Research. 1997 [cited 2007 Jun 2]. Available at: http://www.fda.gov/cder/about/history/Histext.htm.
8. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs. Approved Drug Products with Therapeutic Equivalence Evaluations (27th ed.). 2007 [cited 2007 Jun 2]. Available at: http://www.fda.gov/cder/ob/.
9. Haskins L.S., Tomaszewski K.J., and Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav 7 (2005) 98-105
10. Wilner A.N. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 5 (2004) 995-998
11. Banahan B.F., and Kolassa E.M. A physician survey on generic drugs and substitution of critical dose medications. Arch Intern Med 157 (1997) 2080-2088
12. Welty T.E. Pharmacy and generic substitution of antiepileptic drugs: missing in action?. Ann Pharmacother 41 (2007) 1065-1068
13. Ohio General Assembly. 127th General Assembly Regular Session. 2007 [cited 2007 May 30]. Available at: http://www.legislature.state.oh.us/bills.cfm?ID=127_HB_99.
14. Therapeutics and Technology Assessment Subcommittee, American Academy of Neurology. Assessment: Generic substitution for antiepileptic medication. Neurology 1990;40:1641-1643.
15. Liow K., Barkley G.L., Pollard J.R., Harden C.L., and Bazil C.W. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 68 (2007) 1249-1250
16. Williams RL. Therapeutic equivalence of generic drugs: response to National Association of Boards of Pharmacy [letter]. 1997 [cited 2007 May 29]. Available at: http://www.fda.gov/cder/news/ntiletter.htm.
17. Schachter S. Advisory Committee for Pharmaceutical Science: Open Meeting. 1999 [cited 2007 May 30]. Available at: http://www.fda.gov/ohrms/dockets/AC/99/transcpt/3547t1.rtf.
18. Miller JW, Anderson GD, Doherty MJ, Poolos NP. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy [letter]. 2007 [cited 2007 May 30]. Available at: http://www.neurology.org/cgi/eletters/68/16/1249#8138.
19. Cheeseman Day J, Janus A, Davis J. Computer and Internet use in the United States: 2003. U.S. Census Bureau; October 2005.
20. Berg MJ, Gross RA. Tomaszewski KJ. Zingaro WM, Haskins LS. Generic substitution in the treatment of epilepsy. Neurology, 2008, in press.